曾被跨国药企勃林格殷格翰弃用的FAK抑制剂,如今成了应世生物(InxMed Limited)冲刺港股18A的核心筹码。这家企业低价接手海外“弃药”,跳出行业过往“单药治疗”路径,主打联合疗法,将FAK抑制剂作为“基石药物”嵌套进化疗/ADC/免疫治疗的组合方案中,试图实现资产价值重估。尽管目前二期临床研究已初步取得积极结果,又背靠复星系获得资本与商业化双重加持,但核心产品尚未完成关键三期试验、联合...
Source Link曾被跨国药企勃林格殷格翰弃用的FAK抑制剂,如今成了应世生物(InxMed Limited)冲刺港股18A的核心筹码。这家企业低价接手海外“弃药”,跳出行业过往“单药治疗”路径,主打联合疗法,将FAK抑制剂作为“基石药物”嵌套进化疗/ADC/免疫治疗的组合方案中,试图实现资产价值重估。尽管目前二期临床研究已初步取得积极结果,又背靠复星系获得资本与商业化双重加持,但核心产品尚未完成关键三期试验、联合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.